Intelligent Bio Solutions Announces Strategic Partnership with Vlepis, Provider of Advanced Sensing and Wearable Patch Technologies, to Drive Innovation in Non-Invasive Screening and Consumer Health Monitoring

Rhea-AI Summary

Intelligent Bio Solutions (Nasdaq: INBS) announced a non-exclusive strategic alliance with Vlepis on Dec 18, 2025 to collaborate on R&D, distribution, and regulatory work for non-invasive testing and wearable patch technologies.

The partnership aims to extend INBS’ Intelligent Fingerprinting and SMARTOX SmarTest Patch into consumer health monitoring, leveraging Vlepis’ wearable sensors and cloud/mobile connectivity to accelerate international commercialization and broaden revenue opportunities.

Key Figures

Wearable medical devices market 2024 USD 42.7 billion Global wearable medical devices market size in 2024

Wearable devices 2030 forecast USD 168.3 billion Projected global wearable medical devices market by 2030

Wearables CAGR more than 25% annually Projected annual growth rate to 2030 for wearable medical devices

Consumer healthcare market current USD 383.7 billion Current wider consumer healthcare sector size

Consumer healthcare 2030 forecast USD 548.7 billion Projected wider consumer healthcare sector size by 2030

INBS country footprint more than 24 countries INBS established presence mentioned in partnership release

Market Reality Check

$6.14 Last Close

Volume Volume 131,637 is 5.83x the 20-day average of 22,560, signaling elevated interest ahead of this partnership news. high

Technical Shares at $5.905 are trading well below the 200-day MA of $13.89 and 78.53% under the 52-week high.

Peers on Argus 2 Up

INBS was up 7.36% pre-news with strong volume, while sector peers flagged by momentum (e.g., CODX +5.38%, XAIR +5.21%) were also moving higher, suggesting both stock-specific and broader medical device strength.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 12	Reverse stock split	Negative	-22.7%	1-for-10 reverse stock split to address Nasdaq bid-price compliance.
Nov 20	Conference participation	Neutral	-6.3%	Announcement of participation in Noble Capital Markets growth conference.
Nov 12	Earnings release	Positive	-1.7%	Record fiscal Q1 2026 revenue with higher gross margin and new accounts.
Nov 04	Preliminary results	Positive	-9.1%	Preliminary record Q1 revenue with strong YoY and sequential growth.
Oct 30	Customer growth update	Positive	+8.3%	Added 33 new customer accounts, lifting active accounts to over 480.

Pattern Detected

Recent history shows several negative price reactions to otherwise positive operational updates, while the latest reverse split and Nasdaq compliance actions also coincided with notable downside.

Recent Company History

Over the last few months, INBS has combined operational growth with capital and listing actions. It reported record fiscal Q1 2026 revenue of $1,111,797 and added 33 new customer accounts, building a base of 480+–492 active accounts across 24+ countries. Despite this, shares fell after preliminary revenue and earnings releases. More recently, a 1‑for‑10 reverse stock split and related Nasdaq bid-price compliance steps led to a sharp -22.7% reaction. Today’s Vlepis partnership extends that expansion narrative into consumer health monitoring.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-08-25

INBS has an effective registration framework via an S-3/A dated 2025-08-25 that references Series J Warrants with an initial exercise price of $1.90 per share and up to 4,046,456 underlying shares, exercisable upon stockholder approval. This structure provides flexibility for warrant-driven share issuance alongside existing capital actions such as the recently completed 1-for-10 reverse stock split.

Market Pulse Summary

The stock surged +18.4% in the session following this news. A strong positive reaction aligns with INBS’ strategy of using partnerships to expand its addressable markets. The Vlepis alliance adds wearable sensor and patch technology to its non-invasive testing portfolio and targets large, growing segments, including a wearable medical devices market valued at $42.7B in 2024 and projected to reach $168.3B by 2030. Prior news often saw selling into strength, so investors would have weighed sustainability, funding structures, and potential future share issuance.

Key Terms

wearable patch medical

"Vlepis Pty Ltd (“Vlepis”), an Australian medical and wellbeing technology company specializing in advanced sensing and wearable patch technologies"

A wearable patch is a small, adhesive electronic device that sticks to the skin like a bandage and continuously measures physiological signals (heart rate, temperature, glucose) or delivers medicines. Investors care because these patches can open new recurring-revenue streams, reduce healthcare costs, and generate valuable real‑time data; success depends on clinical reliability, regulatory approval and patient adoption, which drive commercial scale and valuation.

telehealth medical

"Integrated into telehealth and remote-support environments, these capabilities offer better visibility"

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

cloud-based platforms technical

"connect wearable devices (such as its remote monitoring thermometer) with cloud-based platforms and mobile screening applications"

Cloud-based platforms are software and services run on remote computers you access over the internet instead of installing them on your own machine, like renting workspace and tools in a shared building instead of owning a workshop. For investors they matter because they often enable faster growth, predictable subscription revenue, lower upfront costs and easier updates, while introducing dependencies on service providers, internet reliability and data security that can affect a company's value.

mobile screening applications technical

"connect wearable devices (such as its remote monitoring thermometer) with cloud-based platforms and mobile screening applications"

Mobile screening applications are smartphone or tablet programs that collect health information, run simple tests, or guide users through questionnaires and image capture to spot potential medical issues before a formal diagnosis. They matter to investors because they can speed up patient identification, reduce costs, and scale screening like turning a clinic into an app; their value depends on user adoption, data security, regulatory approval, and how well they integrate with healthcare systems.

AI-generated analysis. Not financial advice.

Companies to leverage and collaborate on research and development, distribution, and regulatory expertise to accelerate global adoption of intelligent testing technologies

Alliance positions INBS to enter the fast-growing consumer health market, broadening revenue opportunities beyond commercial screening

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has entered into a non-exclusive strategic alliance and collaboration agreement with Vlepis Pty Ltd (“Vlepis”), an Australian medical and wellbeing technology company specializing in advanced sensing and wearable patch technologies, which better positions INBS to enter the consumer health monitoring market. Vlepis’ wearable and software-based technologies complement INBS’ existing portfolio, which includes its Intelligent Fingerprinting Drug Testing Solution and the recently added SMARTOX SmarTest Patch that the Company distributes.

The global wearable medical devices market, valued at USD 42.7 billion in 2024 and projected to grow at more than 25% annually to USD 168.3 billion by 2030¹, is driving demand for non-invasive health solutions. INBS and Vlepis plan to combine their strengths to meet this growing market segment.

“This partnership with Vlepis strengthens our ability to develop innovative testing and monitoring technologies for new sectors,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “By combining our non-invasive technologies and commercial expertise with Vlepis’ pioneering wearable solutions, we can accelerate entry into the consumer health monitoring sector - a market with strong international demand and long-term revenue potential.”

The partnership will focus on collaboration, leveraging research and development, and expanding distribution networks to strengthen and accelerate international sales and market development. The partnership also provides INBS with the opportunity to evaluate and engage Vlepis’ proprietary enabling technologies and software designed to connect wearable devices (such as its remote monitoring thermometer) with cloud-based platforms and mobile screening applications. INBS will assess how this technology can support its own product ecosystem and create additional value for customers. The relationship creates an opportunity to advance the commercialization of Vlepis’ wearable health and wellbeing patch technologies alongside INBS’ portfolio of non-invasive solutions. Aligning the Intelligent Fingerprinting System and SmarTest Patch with Vlepis’ smart wearables and sensor technologies could extend applications into both business-to-business-to-consumer and direct-to-consumer health markets, including the wider consumer healthcare sector, which is currently estimated at USD 383.7 billion and expected to grow to USD 548.7 billion by 2030².

“Vlepis is delighted to be partnering with Intelligent Bio Solutions, a key innovator in screening technologies. We continue to see substantial value in working with leading med-tech companies to expand our positive impact in health and wellbeing,” said Bill Dimopoulos, CEO and Co-Founder at Vlepis. “INBS’ commercial strength and track record give us the ability to scale faster, while our wearable technologies broaden the scope of intelligent health monitoring. This collaboration will allow us to quickly harness our respective strengths to unlock commercial benefits and disrupt key sectors ripe for transformational change as they digitalize across a range of use cases.”

Vlepis continues to attract strong interest in its sensing solutions. The technology combines innovative design with ease of use, supporting rapid customer deployment and adoption. The company has a clear roadmap of emerging technologies designed to meet broader market needs and use cases.

As connected technologies become standard across care settings, connectivity is emerging as a core component of modern healthcare. Integrated into telehealth and remote-support environments, these capabilities offer better visibility, clearer operational insight, and more responsive care models. This is accelerating innovation across health and wellbeing, especially as demand increases in the aged-care and community support sectors.

In addition, the companies will leverage their collective distributor relationships and regulatory expertise to better position the parties to expedite commercialization in key international markets, building on INBS’ established presence across more than 24 countries.

About Intelligent Bio Solutions Inc. 

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: https://ibs.inc/

About Vlepis Pty Limited

Vlepis is a privately held Australian med-tech solutions company headquartered in Sydney, Australia. Its vision is to be a leading provider of advanced sensing IoT edge-based solutions, including smart wearable patch form factor solutions, integrated sensors, and AI-enabled digital monitoring enablers that deliver scalable healthcare and wellbeing outcomes. Vlepis’ technologies are designed to improve screening and monitoring capabilities across diverse sectors and geographies.

For more information, visit: https://www.vlepis.com/

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact

Intelligent Bio Solutions Inc. 
info@ibs.inc

Investor & Media Contact

Valter Pinto, Managing Director 
KCSA Strategic Communications 
PH: (212) 896-1254 
INBS@kcsa.com

___________________
Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release.

1 Grand View Research 2025. Wearable Medical Devices Market (2025 - 2030). Available at: https://www.grandviewresearch.com/industry-analysis/wearable-medical-devices-market

² Research and Markets 2025. Consumer Healthcare Market – Global Forecast 2025-2030. Available at: https://www.researchandmarkets.com/report/consumer-healthcare

FAQ

What did Intelligent Bio Solutions (INBS) announce on December 18, 2025?

INBS announced a non-exclusive strategic alliance with Vlepis to collaborate on wearable sensing, R&D, distribution, and regulatory support for non-invasive testing and consumer health monitoring.

How will the INBS and Vlepis partnership affect INBS product offerings?

The partnership lets INBS evaluate and integrate Vlepis' wearable sensors and connectivity with its Intelligent Fingerprinting system and SmarTest Patch to expand consumer health applications.

Will the INBS–Vlepis deal change INBS' geographic reach?

The companies said they will leverage distributor relationships and regulatory expertise to expedite commercialization in key international markets building on INBS’ presence in over 24 countries.

Does the collaboration include commercial or regulatory commitments for INBS (Nasdaq: INBS)?

The announcement describes collaboration on R&D, distribution, and regulatory expertise but does not state binding commercial terms, transaction values, or guaranteed regulatory outcomes.

What market opportunity did INBS cite for the partnership with Vlepis?

The release referenced the fast-growing wearable medical devices and broader consumer healthcare markets as opportunities to broaden INBS’ revenue beyond commercial screening.

Will INBS distribute Vlepis wearable patch technologies?

The companies said the relationship creates an opportunity to advance commercialization of Vlepis’ wearable patch technologies alongside INBS’ non-invasive solutions, subject to evaluation and integration.